已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy

作者
Nicolas Roussot,Julie Vincent,Rémi Palmier,Guillaume Constantin,Leïla Bengrine-Lefèvre,Jean-David Fumet,François Ghiringhelli
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:13: 1293670-1293670 被引量:3
标识
DOI:10.3389/fonc.2023.1293670
摘要

Background: Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with platinum chemotherapy was the standard first-line chemotherapeutic regimen until the recent addition of anti-PD-1/PD-L1 antibodies. After disease progression, the only second-line chemotherapy that has demonstrated a survival benefit versus supportive care is FOLFOX (folinic acid, fluorouracil, and oxaliplatin), with a modest benefit. This study aimed to assess the efficacy and safety of second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) combined with bevacizumab for advanced BTC. Methods: This single-center retrospective study enrolled patients with metastatic BTC (intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], or gallbladder carcinoma) that progressed after first-line gemcitabine-based chemotherapy. FOLFIRI-bevacizumab was administered intravenously every 2 weeks [folinic acid 200 mg/m², fluorouracil 400 mg/m² (bolus), fluorouracil 2400 mg/m² (46-h continuous intravenous infusion), irinotecan 180 mg/m², and bevacizumab 5 mg/kg] until unacceptable toxicity, patient refusal, or disease progression. Results: Overall, 28 patients received the FOLFIRI-bevacizumab regimen after gemcitabine-based chemotherapy. The median overall survival (OS) was 9.0 months (95% CI 6.4-16.5). The OS rate was 39.3% (95% CI 24.8-62.3) and 10.7% (95% CI 3.7-32.1) at 12- and 24-months respectively. The median progression-free survival (PFS) was 5.2 months (95% CI 3.1-10.2) with FOLFIRI-bevacizumab. The PFS rates at 12 months and 24 months were 17.9% (95% CI 8.19-39.5] and 10.7% (95% CI 3.7-31.2), respectively. The overall response rate (ORR) to FOLFIRI-bevacizumab was 23.1%, with a disease control rate (DCR) of 69.3%. Grade 3-4 adverse events (sAE) were reported in 20 patients (71.4%) treated with FOLFIRI-bevacizumab. Conclusion: FOLFIRI-bevacizumab as a second-line treatment for advanced BTC after gemcitabine-based chemotherapy showed efficacy and safety with a promising tumor response rate in this retrospective single-center study.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Owen的应助被科研通管家采纳,获得30
刚刚
DW的应助被科研通管家采纳,获得10
刚刚
充电宝的应助被科研通管家采纳,获得10
刚刚
刚刚
斯文败类的应助被科研通管家采纳,获得10
刚刚
1秒前
1秒前
Akim的应助被科研通管家采纳,获得30
1秒前
斯文败类的应助被科研通管家采纳,获得10
1秒前
FashionBoy的应助被科研通管家采纳,获得10
1秒前
狂野采波发布了新的文献求助10
1秒前
王思聪完成签到 ,获得积分10
2秒前
Lucas的应助被ezekiet采纳,获得10
2秒前
丘比特的应助被xy采纳,获得10
2秒前
Jasper的应助被Zhixia采纳,获得10
2秒前
wwwww发布了新的文献求助10
3秒前
FoxLY完成签到,获得积分10
3秒前
灵巧的寄容完成签到,获得积分10
3秒前
4秒前
科研通AI2S的应助被Crane采纳,获得10
4秒前
Yaang发布了新的文献求助100
4秒前
Csy发布了新的文献求助20
5秒前
5秒前
畅快的绮完成签到,获得积分10
5秒前
qzq完成签到,获得积分20
7秒前
7秒前
高兴香彤发布了新的文献求助10
8秒前
大个的应助被cxy2采纳,获得10
8秒前
8秒前
酣畅淋漓的下载大师完成签到 ,获得积分10
9秒前
搜集达人的应助被魏魏采纳,获得10
10秒前
搜集达人的应助被木华采纳,获得10
10秒前
szxa发布了新的文献求助10
10秒前
哈哈哈哈发布了新的文献求助10
11秒前
perway发布了新的文献求助10
12秒前
林夕发布了新的文献求助10
12秒前
13秒前
13秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643